Circular RNAs in Cardiovascular Diseases: Molecular Mechanisms, Therapeutic Advances, and Innovations

Zheng Yuan, Shaoyuan Huang, Xin Jin, Shanshan LiGenes 2024 · DOI

TL;DR

Circular RNAs (circRNAs) are a novel class of RNA molecules with unique structures and regulatory roles, showing great promise as therapeutic targets for cardiovascular diseases (CVDs). This review synthesizes current knowledge on circRNAs in CVDs, detailing their mechanisms, therapeutic strategies like small-molecule drugs and synthetic sponges, and the critical need for advanced delivery systems to translate this potential into clinical reality.

What Problem Does This Paper Address?

Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide, and despite advances, there's an urgent need for novel therapeutic strategies. Traditional risk factors are well-known, but the increasing prevalence in younger populations highlights the need for new approaches. Non-coding RNAs, particularly circRNAs, have emerged as key players in regulating gene expression and are implicated in various CVD pathologies. However, translating the therapeutic potential of circRNAs into effective treatments faces significant hurdles, including their stability, tissue specificity, and efficient delivery into target cells. This paper addresses the need for a comprehensive overview of circRNAs in CVDs, covering their fundamental biology, their roles in disease, and the current and future therapeutic strategies, with a focus on overcoming delivery challenges.

Methods

This paper is a review article, so it doesn't present novel experimental methods. Instead, it synthesizes and analyzes existing research. The authors draw upon a wide range of published studies, including:

  • RNA sequencing techniques: Used to identify and characterize circRNAs and their expression patterns in various disease states.
  • Molecular biology techniques: Such as RNA pull-down assays, luciferase assays, and gene knockdown/overexpression studies, used to elucidate the molecular mechanisms of circRNA function (e.g., miRNA sponging, protein interactions).
  • Animal models: Including mouse models of myocardial infarction, cardiac hypertrophy, and fibrosis, used to study the in vivo roles of circRNAs and test therapeutic interventions.
  • In vitro cell culture studies: Employed to investigate circRNA function in specific cell types, like cardiomyocytes.
  • Drug development strategies: Including the design of small-molecule drugs and synthetic circRNA sponges.
  • Delivery system development: Research on viral vectors (AAVs, lentiviruses), non-viral systems (lipid nanoparticles, polymeric nanoparticles), and exosomes for efficient RNA delivery.

The novelty lies in the comprehensive integration and critical evaluation of these diverse research findings within the context of cardiovascular medicine.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing literature rather than presenting new experimental data or analyses of specific datasets.

Key Insights and Ideas

  • CircRNAs are more than just "junk": Initially overlooked, circRNAs are now recognized as crucial regulators of gene expression with unique stability due to their covalently closed-loop structure. This stability makes them ideal candidates for therapeutic interventions.
  • CircRNAs as "miRNA sponges": A primary mechanism of circRNA action is sequestering microRNAs (miRNAs), thereby modulating the expression of target genes. This "sponge" activity is central to their role in various CVDs.
  • Diverse roles in CVD pathology: CircRNAs are implicated in key cardiovascular processes like cardiomyocyte apoptosis and repair, cardiac hypertrophy, myocardial infarction, fibrosis, and heart failure, acting as both contributors to disease and potential regulators of recovery.
  • Therapeutic avenues are emerging: Beyond simply understanding their roles, researchers are actively developing strategies to harness circRNAs therapeutically. This includes:
  • Small-molecule drugs: Designed to target specific circRNA structures or their interactions, offering a precision medicine approach.
  • Synthetic circRNA sponges: Engineered molecules that mimic natural circRNAs to precisely modulate miRNA activity.
  • Delivery is the bottleneck: The biggest challenge for circRNA therapeutics is getting them to the right place in the body, in sufficient quantities, and without triggering adverse immune responses. This is driving innovation in viral, non-viral, and exosome-based delivery systems.

Key Results

The paper doesn't present specific quantitative results from a single experiment but rather summarizes findings from numerous studies:

  • Identification of specific circRNAs: Numerous circRNAs (e.g., circSAMD4A, circITCH, circNCX1, MFACR, circPan3, circSlc8a1, circRNA_000203, circHRCR, circFNDC3b, circNfix, circNFIB, MICRA) have been identified and linked to specific CVD pathologies.
  • Demonstrated therapeutic effects in preclinical models:
    • Overexpression of circFNDC3b improved left ventricular function and reduced ischemic damage in mouse MI models.
  • Knockdown of circNCX1 reduced apoptosis in ischemic myocardial injury models.
  • Synthetic circRNA sponges have shown efficacy in mitigating cardiac hypertrophy in animal models.
  • Small-molecule drugs targeting RNA are showing promise in other diseases (e.g., risdiplam for SMA), suggesting potential for CVDs.
  • Delivery system advancements: Various delivery systems (AAVs, LNPs, exosomes) have demonstrated successful delivery of circRNAs or related molecules (like circmiRs) to target cells (e.g., cardiomyocytes) in preclinical settings, showing potential to improve cardiac function and reduce disease markers.

Limitations and Future Work

  • Preclinical reliance: The vast majority of current research is based on animal models and in vitro studies. The direct relevance and applicability of these findings to human physiology and complex human cardiovascular diseases remain uncertain.
  • Hypothetical therapeutic implications: While many circRNAs show promise, their therapeutic potential is largely hypothetical at this stage. No circRNA has yet been definitively proven to have diagnostic or therapeutic value in human CVDs.
  • Transition to human trials: Bridging the gap between preclinical findings and clinical applications is a major challenge. This requires comprehensive preclinical validation and well-designed clinical trials to establish safety, efficacy, and specificity.
  • Delivery system optimization: Significant challenges remain in achieving tissue-specific targeting, minimizing immune responses, ensuring long-term stability, and facilitating efficient intracellular delivery of circRNAs.
  • Future Directions:
    • Further validation of circRNA roles and therapeutic potential through rigorous preclinical and clinical studies.
  • Development of advanced, tissue-specific delivery systems to overcome current limitations.
  • Understanding the long-term impact of circRNA modulation on gene expression and potential immune reactions.
  • Integration of circRNA technologies into personalized medicine approaches for CVDs.

Summary updated

Abstract

Circular RNAs (circRNAs) have emerged as promising therapeutic targets due to their unique covalently closed-loop structures and their regulatory roles in gene expression. Despite their potential, challenges in circRNA-based therapies include ensuring stability, tissue specificity, and efficient intracellular delivery. This review explores the implications of circRNAs in cardiovascular diseases (CVDs), providing an overview of their biogenesis, molecular mechanisms, and roles in disease pathology. In addition to discussing molecular features, this review highlights therapeutic advances, including small-molecule drugs targeting circRNAs, synthetic circRNA sponges, and innovations in drug delivery systems that enhance the effectiveness of these therapies. Finally, current challenges and future directions are addressed, emphasizing the need for continued research to fully unlock the therapeutic potential of circRNA-based strategies in cardiovascular medicine.
BibTeX
@inproceedings{yuan2024circular,
  author = {Zheng Yuan and Shaoyuan Huang and Xin Jin and Shanshan Li},
  title = {{Circular RNAs in Cardiovascular Diseases: Molecular Mechanisms, Therapeutic Advances, and Innovations}},
  booktitle = {Genes},
  year = {2024},
  doi = {10.3390/genes15111423},
}
Figure